PPT-Peginterferon alfa -2a+/- Ribavirin

versus Interferon alfa2b Ribavirin Phase 3 Treatment Naïve Chronic HCV Fried MW et al N Engl J Med 2002347975 8 2 Peginterferon Ribavirin versus Interferon Ribavirin. for Patients with Prior Failure to PEG + RIB. PROVIDE. Phase . 3. Treatment. . Experienced. Vierling. JM, . et al. . J . Hepatol. . 2013;Dec 19 [. Epub. ahead of print].. Source: . Vierling. . JM, et al. J . versus . Telaprevir. . with PR in GT1 . ATTAIN Trial. Phase . 3. Treatment. . Experienced. Reddy KR. , . et al. . Lancet Infect Dis. 2015;15:27-35.. Source: Reddy KR. , et al. Lancet Infect Dis. 2015;15:27-35.. alfa-2a . versus. . Interferon . alfa-2a. Phase 3. Treatment. . Naïve, Chronic HCV. Zeuzem. S, et al. N . Engl. J Med. 2000;343:1666-72.. Source: . Zeuzem. S, . et al. . N Engl J Med. 2000;343:1666-72.. versus. . Interferon alfa-2b + Ribavirin . Phase 3. Treatment. . Naïve, Chronic HCV. Manns. . MP, et. al. Lancet. 2001;358:958-65. Peginterferon alfa-2b + Ribavirin . versus . Interferon alfa-2b + Ribavirin . Pegasys. ). Prepared by: David Spach, MD & H. Nina Kim, MD. Last Updated: February . 14, . 2014. Background and Dosing. Peginterferon alfa-2a (. Pegasys. ). Peginterferon alfa-2a (. Pegasys. ). Summary. Overview. . of. . PECS . projects. European Space . Agency Information . Day. 1. 1. th. January. , 2017. Point of Contact: . Ms. . Maite. Trujillo: maite.trujillo@esa.int. Mr. Laurent . Marchand. SPRINT-2. Phase 3, Treatment . Naive. Treatment. . Naïve. Source: . Poordad F, . et al. . N Engl J Med. 2011;364:1195-206.. Boceprevir . for Treatment-Naïve HCV Genotype 1. SPRINT. -2 Trial: Study Design. Using . SiPM. to readout Scintillating Fibers . What has been done for ALFA. The “Scintillating Fibers & . SiPM. ” status of the art. . ALFA. . SiPM. Collecting Information. Starting discussion. Flat versus Weight-Based Ribavirin Dosing. Phase . 3. Treatment. . Naïve, Chronic HCV. Jacobson IM, et. al. Hepatology. 2007;46:971-81.. *Weight-based . ribavirin. dosing: < 65 kg: 800 mg/. d. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . RBV . versus. Interferon alfa. -. 2a + RBV . ACTG 5071. Phase . 2. Treatment. . Naïve, Chronic HCV and HIV. Chung RT, . et. al. N . Engl. J Med. . 2004;351:451-9. . PEG alfa. -2a . + . RBV . versus. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology . 2015;148:100-7. Treatment Naïve and Treatment Experienced Liver Transplantation Source: Curry MP, et Editorial April 2018 Alfa Laval reserves the right to change specifications without prior notification. Smooth - running ballast water treatment with Alfa Laval PureBallast 3 Dowa Line, USA, Case s . Interferon . alfa-2a. Phase 3. Treatment. . Naïve, Chronic HCV. Zeuzem. S, et al. N . Engl. J Med. 2000;343:1666-72.. Source: . Zeuzem. S, . et al. . N Engl J Med. 2000;343:1666-72.. Peginterferon alfa-2a versus Interferon alfa-.